Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers found that TCDD exposure accelerated differentiation and altered gene expression in human epidermal cells, indicating the epidermal barrier as a target of TCDD-activated AHR.

This review discusses the complication of vitiligo in patients undergoing diphencyprone sensitization therapy for alopecia universalis and reports no new clinical findings.

This article presents an overview of uncombable hair syndrome, emphasizing its clinical and molecular characteristics and noting systemic manifestations such as neuropsychiatric, ophthalmic, and cardiopulmonary issues.

In this retrospective case series, therapeutic responses to immunomodulatory and incretin-based therapies for Dercum's disease showed considerable individual variation, suggesting these treatments might be exploratory options when surgery isn't feasible, though further controlled studies are needed for definitive conclusions.

In a case report, complete hair regrowth was observed in a patient with severe alopecia areata after treatment with deucravacitinib, a TYK2 inhibitor, suggesting new therapeutic avenues for alopecia areata despite TYK2 not being traditionally linked to this condition.

No abstract is available for this article, and it presents no new clinical results.

This article discusses the FDA approval of dutasteride for benign prostatic hypertrophy and explores its potential role in treating androgenetic alopecia but reports no new clinical findings.

In this study, tofacitinib treatment in a male patient with alopecia areata led to significant hair regrowth and improvement in nail dystrophy symptoms, restoring finger function within 10 months.

In this case report, a female patient with both psoriasis and lichen planus initially responded to acitretin and topical mometasone but experienced a relapse after stopping the treatment. The authors reported marked improvement within 3 months after switching to upadacitinib, aiming to guide clinical decision-making.

This study established a rapid and accurate ultra-performance liquid chromatographic method for chemical fingerprinting and analyzing Platycladi cacumen, effectively distinguishing batches based on geographical and climatic conditions.

This entry contains no research abstract, so no scientific findings or conclusions are reported.

In this study, researchers found that applying mometasone furoate 0.1% cream combined with adapalene 0.1% gel resulted in significantly greater hair regrowth over 12 weeks compared to mometasone furoate cream alone in patients with alopecia areata.

This meta-analysis found that deuruxolitinib significantly improved hair regrowth and patient satisfaction in those with moderate to severe alopecia areata compared to placebo, though it was associated with manageable side effects such as elevated creatinine kinase levels, headaches, and acne, especially at higher doses.

This report documents a case where a man survived sub-acute toxicity from an overdose of the anticancer drug UFT due to effective treatment with antibiotics and granulocyte colony-stimulating factor.

This review highlights the demonstrated efficacy and growing use of upadacitinib for cutaneous disorders, emphasizing its cost-effectiveness and recent availability in India compared to other biologics and small-molecule therapies, rather than providing new primary data.

This study found that baricitinib can counteract the cytokine-driven reduction of the enzyme PADI1 in human keratinocytes, which may help improve skin barrier function in atopic dermatitis by enabling epidermal differentiation.

This article discusses treatments for androgenic manifestations using cyproterone acetate alone or with estrogens, but it does not provide new clinical results.

Deuruxolitinib improves anxiety and depression in severe alopecia areata patients.

3D ultrasound can detect hair follicle changes and disease phases in alopecia areata.

This review discusses the approval of deuruxolitinib, an oral JAK inhibitor, by the FDA in July 2024 for treating severe alopecia areata in adults, highlighting its role as the third approved oral treatment option alongside baricitinib and ritlecitinib.

This study found that dutasteride 0.5 mg was generally well-tolerated and led to overall improvement in male patients aged 18 to 41 with androgenic alopecia in a Korean clinical practice setting.

This case report describes a patient with psoriasis, vitiligo, and alopecia areata who showed significant improvement in all conditions after treatment with ustekinumab, suggesting potential benefits of IL-12/23 blockade for these autoimmune diseases.

This study found that Baricitinib significantly reduced hair loss and immune response in a mouse model of alopecia areata.

In this retrospective study, researchers found a statistically significant increase in the risk of alopecia areata among atopic dermatitis patients using dupilumab compared to controls, suggesting the need for careful monitoring and further research on the drug's impact on alopecia areata.

This letter discusses azathioprine-induced alopecia and leukopenia potentially linked to NUDT15 polymorphisms, reporting no new clinical results.

Genetic factors, especially PADI3 gene variants, contribute to CCCA in women of African descent.

This study found that dutasteride pretreatment reduced certain sedative effects of alcohol and may decrease drinking behavior in adult men, likely by impacting neuroactive steroid levels.

This study reports that the metanephrine content was significantly higher in patients with alopecia areata compared to those without the condition.

This review discusses the use of dutasteride for treating androgenetic alopecia and reports no new clinical results.

This review describes how dutasteride, a dual 5alpha-reductase inhibitor, has improved outcomes in benign prostatic hyperplasia and is being studied for prostate cancer prevention, without new data reported.